

Genomic Instability and Cancer Genetics

Chang Chan, PhD
Cristina Montagna, PhD

April 26, 2023

RUTGERS
Cancer Institute
of New Jersey
RUTGERS HEALTH



Genomic Instability and Cancer Genetics



Cristina Montagna, PhD

Professor
Radiation Oncology

- NCI R21
- NCI U54 Subproject
- NIA RF1
- DoD (3)

Montagna's Role in Program

- Aims 1 and 2
- Experimental Sciences



Chang S. Chan, PhD

Associate Professor
Medicine

- NET ResFndtn

Chan's Role in Program

- Aim 3
- Computational Sciences

Shared Program Responsibilities

- Co-leaders share responsibilities in all aspects of the program, while each has a leading role in certain aspects of the program
- Translational and team projects
- Monthly Program meetings
- Pilot awards
- NIA nominations
- Education, DEI, catchment
- Membership
- Interactions with PU

Program Aims

AIM 1

To elucidate the **core mechanisms that provoke genomic instability**, including imprecise repair of DNA damage, DNA replication infidelity, and chromosome segregation errors

AIM 1

Bunting	Patel
Ganesan	Petry* 
Gartenberg	Schindler
Georgopoulos	Shen
Herbig	Tischfield
Madireddy*	Xia
McKim	Zaratiegui

*New Member

Program Aims

AIM
1

To elucidate the **core mechanisms that provoke genomic instability**, including imprecise repair of DNA damage, DNA replication infidelity, and chromosome segregation errors

AIM
2

To understand the **coordination between genome maintenance machinery and intrinsic cellular homeostasis**, and their contribution to tumor initiation and progression

AIM 2

Copeland	Perekatt*
Feng	Pestov*
Gu	Rasin
Hu	Roth
Levine 	Verzi
Libutti	Zamudio*
Montagna*	Zhou*

*New Member

Program Aims

- AIM 1** To elucidate the **core mechanisms that provoke genomic instability**, including imprecise repair of DNA damage, DNA replication infidelity, and chromosome segregation errors
- AIM 2** To understand the **coordination between genome maintenance machinery and intrinsic cellular homeostasis**, and their contribution to tumor initiation and progression
- AIM 3** To characterize the **cancer genome landscape** and gene expression signatures to reveal therapeutic vulnerability


AIM 3

Adamson* 	Kreimer*
Bhanot	Mitrofanova*
Chan, C	Raphael 
Chan, M* 	Shah*
De	Singh 
Grigoriev*	Troyanskaya 

*New Member

Program Membership Profile


Membership




2023

- 20 Departments
- 8 Schools
- 3 Universities
- 1 Institute
- 12 New Members

Total Cancer Relevant Funding




R01 Equivalents



2018: 18 PIs/PDs
2023: 19 PIs/PDs


Program Productivity and Collaborations

Total Publications



■ 2018 Submission ■ 2023 Submission


Collaborative Publications



■ 2018 Submission ■ 2023 Submission

High impact publications (IF ≥ 10): 38% (198)
Publications with citations ≥ 10: 38% (201)

Collaborative Publications with Other Institutions



■ 2018 Submission ■ 2023 Submission

Response to Prior Critique

Scored **Excellent**

- Improved clinical translation of cancer genomics studies
 - Developed LOHGIC and All-FIT, routinely used by Molecular Tumor Board
 - Identified truncated form of FGFR2 as an oncogenic driver targeted in clinical trials
 - Calculated HRD scores and applied to breast cancer therapeutic trials
 - Defined a genomic signature of CHIP and used to evaluate potential AEs in breast cancer therapy
- Improved collaborations among members from Consortium institutions
 - CINJ pilot awards (Verzi/Toettcher[🏆], and De/Raphael[🏆])
 - NJACTS award (Petry[🏆]/Shen)
 - Mutational variants of unknown significance (Singh[🏆], C. Chan, Ganesan)
 - Single cell-based synthetic lethality/viability screen for DNA repair genes using PerturbSeq (Adamson[🏆], Xia, Shen, Ganesan)
 - Targeting spindle-formation factors in mitosis (Petry[🏆], Shen)



Scientific Impact of Program

Fundamental mechanisms

- Centrosome-independent branching microtubule nucleation during mitotic spindle formation
- New cellular origin of colorectal cancer due to ectopic crypt formation resulting from villi de-differentiation
- Non-canonical roles of the Trp53 in tumor progression
- Microbial signatures in colorectal and pancreatic cancers

Tools and drivers for precision oncology



Grants:

- R01GM141100 (Petry)
- R01DK121915 (Verzi)
- R01DK126446 (Verzi)
- R01CA229257 (Feng)


Publications:

- Petry, *Nat Cell Biol* 2018
- Petry, *Nat Commun* 2020
- Verzi, *Cancer Res* 2018
- Verzi, *Nat Genet* 2019
- De, *Cancer Cell* 2022

Branched Microtubule Formation Without Centrosome (Petry)



BRCA Network in DNA Damage Response, Tumor Development, and Therapeutic Response



Shared Resources

- Genome Editing
- Biospecimen Repository and Histopathology
- Comprehensive Genomics
- Immune Monitoring

Grants



- P01CA250957
- R01CA138804
- R01CA195612
- R01CA262227
- R01CA260724
- R01GM129066

Publications

- Bunting, *Mol Cell Biol* 2018
- Xia, *Oncogene* 2019
- Xia, *Nat Commun* 2021
- Xia, *Cancer Res* 2021
- Shen, *Cell Reports* 2022

Major Discoveries

- BRCA2-MCM10 interaction suppresses PRIMPOL-mediated ssDNA gap formation upon DNA damage
- Inter-tissue difference in DNA damage response revealed in *Brca2* and *Palb2* KO mice
- Structural basis of PALB2 homo-dimer
- Differential roles of BRCA1-PALB2 and PALB2-BRCA2 interactions in G2/M checkpoint activation and maintenance



Impact

Investigate DNA damage response (DDR) networks across cell types and conditions to reveal new therapeutic vulnerabilities

Catchment Priority

Breast Cancer
Hereditary Cancer

Tissue Homeostasis Dictates the Susceptibility to Colorectal Cancer

AIM
2



Verzi



Perekatt



Gao
(CMI)



White
(CMI)



Ganesan
(CIPT)



Montagna

Shared Resources

- Genome Editing
- Comprehensive Genomics

Grants


- CINJ pilot award
- R01CA190558
- R01DK121915
- K22CA218462

Publications


Perekatt/Verzi, *Can Res* 2018
 Chen/Verzi, *Nat Genet* 2019
 Kumar/Verzi, *Development* 2019
 Chen/Verzi, *Gastroenterology* 2020
 Chen/Verzi, *Cell Reports* 2021
 Verzi, *Oncogene* 2022

Major Discoveries

- SMAD4 dampen epithelial differentiation and enhance BRAF and WNT oncogenic functions
- Dedifferentiation expands cells of origin for WNT-driven oncogenesis
- SMAD4 and HNF4 maintain tissue homeostasis via feed-forward loop



Ectopic crypt formation from villi upon SMAD4 deletion and expression of GOF b-catenin



- Montagna/Jabbour: U54 Radiation Oncology-Biology Integration Network (ROBIN) (1U54CA274291)

Impact

Paradigm shifting theory of new cellular origin for colorectal cancer

Catchment Priority
Colorectal Cancer

New Insights into the Landscapes of Cancer Genomes: Reconstruction of Clonal Evolution

AIM
3



Raphael



Khiabian
(former GICG)



Riedlinger
(CIPT)



Ganesan
(CIPT)



De

Shared Resources

- Biomedical Informatics

Grants


- U24CA211000
- R01GM129066
- R01CA233662
- R21CA248122

Publications


- Khiabian, *JCO Prec Oncol* 2019
- De, *Cell Rep* 2019
- Raphael, *Genome Res* 2020
- Raphael, *Nat Comm* 2020
- Raphael, *Cell Syst* 2020
- Raphael, *Nat Biotech* 2021

Major Discoveries

- CHISEL: characterizing allele and haplotype specific copy number alterations in single cells
- SCARLET: single-cell tumor phylogeny inference with copy number-constrained mutation losses
- Detection of distinct clonal populations in cell-free DNA
- Non-genetic intra-tumor heterogeneity is a major predictor of phenotypic heterogeneity and evolutionary dynamics in lung tumors



Haplotype-specific copy-number tree (3,994 supported SNVs)



Impact

Breakthrough in knowledge of how cancers evolve and respond to treatment

Catchment Priority

Relevant to all catchment priority cancers

Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Solid Tumor Microenvironment: Translational Research

AIM
3



Khabanian
(former GICG)



Ganesan
(CIPT)



Toppmeyer
(CIPT)



Riedlinger
(CIPT)

Shared Resources

- Biospecimen Repository and Histopathology
- Biomedical Informatics

Grants

- R01CA233662


Publications

Severson/Khabanian, *Blood* 2018

Riedlinger/Khabanian, *JAMA Oncol* 2019

Clinical Challenges

Molecular Tumor Board (MTB) faces challenges in utilizing sequencing data for clinical management of cases with multiple mutations at varying frequencies.



Impact

Analytical tools implemented in the MTB to interpret mutational variants

Catchment Priority

Relevant to all catchment priority cancers

Research Responsive to Catchment Area



Xia
(COE Liaison)



De



Madireddy



Ganesan
(CIPT)

Shared Resources

- Genome Editing
- Biomedical Informatics
- Comprehensive Genomics

Grants

- R01GM129066
- R00HL136870

Publications

- De, *Cell Rep* 2019
- De, *NAR Cancer* 2021
- De, *JCO-PO* 2022
- De, *Cancer Cell* 2022
- Madireddy, *Nature Medicine* 2022

Major Discoveries

Cancer Types with High Mortality

- Distinct oncogenic fusions associated with clustered oxo-G linked to potential exposure to microbial metabolism in colorectal cancer

Environmental Risk Factors

Dust exposure

- Some NJ and Tri-state area first responders and residents have higher cancer rates from 9-11 fallout dust exposure; dust increased mutation and replication fork speeds (**Madireddy**)


Plastic exposure

- Microplastic pollutants (MPP) were found in NJ river water, which is concerning given the state's long and dense coastline population
- Unique mutation signature found in cells exposed to main components of MPP, as well as in kidney and gastrointestinal cancers of elderly patients (**De**)


Catchment Priority

Colorectal Cancer

Contribution of Gut Microbes in Oncogenic Fusions of Mismatch Repair Defective CRC




Additional Examples of Catchment Area Responsiveness



Catchment Area Responsive Research in the Program


- 43% publications and 45% of grants are directly relevant to catchment priorities
- Involves the basic mechanisms of multiple cancer types: breast, colon, lung, etc.
- Addresses multiple cancer risk factors: hereditary, environmental exposure, HPV, etc.



Collaboration and Communication with COE and Community

- COE provided the microplastic pollutant and colorectal cancer data for New Jersey
- Xia, Zhou, Pine, and others participated in COE's Community Science Cafés
- Hu, Madireddy hosted trainees from the community outreach and training program (RUYES)


Colorectal Cancer Incidence & Microplastic Densities
Raritan & Passaic Rivers
New Jersey, by County and Sample Site




Data: Ravit, et al (2017); NY/NJ Baykeeper (2016); Cohen (2017)

Education and Training within Program


MCF shCtrl + Dox



MCF sh56 + Dox




Shaimaa Hussein
PhD trainee



Eleanor Agosta
MD/PhD candidate



RUYES Field Trip



RUYES community
outreach: Linden High
School (Hu)

Training Award Mentors/PIs

- NCI-K22 and NCI-K99
- NIH F30, F31 fellowships
- 41 NJCCR postdoctoral/pre-doc fellowships
- Mentors for the CMI T32 postdoc training award
- Hosts for the RUYES program

Research Training

- Graduate students and postdocs: 118 current and 122 new recruits since 2018
- 12% URG trainees (14 current and 15 since 2018)

Directors and Lectures for Major Classes

- Radiation Cancer Biology (2 semesters/ year), req. for Rad Onc residents (Shen/Xia/Hu/Feng)
- Molecular Biosciences graduate program
 - Mini-Course in Molecular Biosciences: p53 (Hu/Feng)
 - Spec Top Cell Mol Pharm: Mol Response Therapeutic DNA Damage (Xia/Shen)
- Guest lectures (Shen, Hu, Feng): NYU Env Carcinogenesis

Value Added: Center to Program

Development Funds

One New
Investigator Award
\$50,000

**REACH
Award**

Pilot awards including
CETI and Cancer Health
Equity Awards
\$350,000

**RWJF
Award**
(contributed to P01)

Shared Resources

- Genome Editing
- Comprehensive Genomics
- Immune Monitoring/ Flow Cytometry
- Biospecimen Repository and Histopathology Services
- Biostatistics
- Biomedical Informatics

Meetings and Retreats

- Program
- DNA Repair Working Group
- Cancer Genomics Working Group
- PU-RU joint symposia
- Annual Retreats

Member Recruitment

- 12 new members
- 7 consortium members

Center Administration

- Central Laboratory Services
- Grants Office
- Faculty Recruitment
- IST
- Multi-Project Application Support
- Medical Writer Services
- Specialized Research Administrative Support
- Strategic Planning Facilitation
- Workforce Development

PED

Guidance to diversify
research teams

COE

Educational sessions and
updates on relevant issues
at Program meetings

Value Added: Program to Center

Providing foundation for team science

- P01 offers a platform for DNA repair collaborations
- MPI projects
- Multiple inter-institutional teams

Fueling forward and reverse translation and supporting clinical projects

- Rational Neoadjuvant Rx targeting HRD in TNBC
- LIF1 to modulate radiation effects and to protect from GvHD pathologies
- Imputation of tumor purity and CHIP from high-depth clinical sequencing data
- Detection of actionable driver mutations
- Multiple preclinical therapeutic studies under development

- **Addressing multiple catchment priorities:** cancer types and risk factors

- **Education:** mentorship to trainees in R25, T32, and residency programs

PED

12% URG trainees

COE

Multiple community outreach bidirectional communication activities

Future Plans

1 Establish new areas of scientific excellence and technological advancement


- Chromosomal instability and tumor microenvironment
- Advanced genomic technologies

2 Promote synergistic team science

- Pilot awards to teams that strengthen consortium collaborations
- Multidisciplinary studies: SPORE in NET; new functions of TP53; additional MPI R01s

3 Expand scope of translational science

- Work with CETI to promote pre-clinical studies
 - Validating new mechanism of mitotic spindle formation as a target for cancer therapy
 - Truncated form of FGFR2 as a therapeutic target
 - DNMT1 inhibitor in MEN1 deficient tumor
 - TOP1, PARP1, G9a inhibitors in BRCAness medulloblastomas and breast cancer
 - CDK6 and aromatase inhibitors in combination with radiotherapy
- Forward- and reverse-translational studies: characterizing new driver variants identified by Precision Oncology



Thank You

Q&A Segment



RUTGERS
Cancer Institute
of New Jersey
RUTGERS HEALTH

